Kornimate/medical-research-clean huggingface dataset:
changyanning tablet for the treatment of diarrhea-predominant irritable bowel syndrome (ibs-d)

Conditions: Diarrhea-Predominant Irritable Bowel Syndrome

Summary: the goal of this clinical trial is to test the efficacy and safety of the chinese patent medicine changyanning tablet in the patients with diarrhea-predominant irritable bowel syndrome (ibs-d). the main questions it aims to answer are: 1. can changyanning tablet improve diarrhea and abdominal pain in ibs-d patients? 2. is changchangning tablet safe for the treatment of ibs-d?


Eligibility criteria:
inclusion criteria: 1. meet ibs-d rome iv diagnostic criteria; 2. age between 18 and 65 years old (including boundary value), regardless of gender; 3. ibs symptom severity scale (ibs-sss) scores \> 175 points; 4. the weekly average score of abdominal pain in screening period is ≥ 3 points (the most severe abdominal pain in the past 24 hours every day, the pain score was 11 grades (0-10), nrs-11; also the number of days of the stool character classification (bristol stool scale) is type 6 or 7 ≥ 2 in a week; 5. patients who voluntarily accept the program's plan of the project and signs the informed consent form. exclusion criteria: 1. patients with serious or unstable heart, liver, kidney, immune, endocrine system and other diseases or malignant tumors; 2. patients are affected by factors such as intellectual disorder, mental disorder and language; 3. patients with gastrointestinal organic diseases or with malignant tumors, such as pancreatitis, intestinal adenoma (excluding polypectomy for more than half a month), intestinal diverticulum, colon or rectal cancer, inflammatory bowel disease, intestinal tuberculosis, etc; 4. other diseases (such as hyperthyroidism, diabetes, chronic renal insufficiency, nervous system diseases, etc.) that affect digestive tract dynamics; 5. complicated with tuberculosis peritonitis, gallstones, cirrhosis, chronic pancreatitis and other gastrointestinal diseases; 6. allergic constitution or allergic to the components of the studied drug; 7. pregnant or lactating women, and women with recent fertility plans; 8. previous abdominal or pelvic surgery, such as cholecystectomy; 9. patients with positive fecal occult blood; 10. during the screening period, drugs that affect gastrointestinal motility and function cannot be stopped, including parasympathetic inhibitors, such as scopolamine, atropine, belladonna, etc; muscle relaxants, such as succinylcholine; antidiarrheal agents such as loperamide, smecta, etc; opioid preparations, etc; 11. those who use probiotics (except those who eat yoghurt) or antibiotics within 8 weeks before enrollment in the study; 12. ibs drugs (except polyethylene glycol and loperamide) were used within 3 months before the study; 13. those who regularly drink alcohol within 6 months before screening, i.e., drink more than 14 units of alcohol every week (1 unit=360 ml beer or 45 ml liquor or 150 ml wine with 40% alcohol); 14. those who have participated in or are currently participating in other clinical trials within 1 month before screening; 15. the researcher believes that there are patients who are not suitable for inclusion.
impact of enhanced information on subjective information level and proms in patients with aortic stenosis

Conditions: Aortic Stenosis Disease

Summary: the aim of this trial is to evaluate if an enhanced information by using a mobile app can increase subjective information level in patients with severe aortic stenosis and may therefore improve patient-reported outcomes.


Eligibility criteria:
inclusion criteria: * severe aortic valve stenosis * planned aortic valve replacement (tavi) * patient is willing and able to complete the surveys in german language * written informed consent by the trial subject exclusion criteria: - language barrier

Keywords: aortic stenosis mobile app
study of meloxicam capsules in subjects with osteoarthritis of the knee or hip

Conditions: Osteoarthritis

Summary: the purpose of this study is to evaluate the safety of meloxicam solumatrix capsules for up to 52 weeks in subjects with pain due to osteoarthritis (oa) of the knee or hip


Eligibility criteria:
inclusion criteria: * is male or female ≥ 40 years of age * if a participant in the previous mel3-12-02 study, completed the study and did not discontinue for lack of efficacy or safety * has a diagnosis of oa of the hip or knee with ongoing knee and/or articular hip pain * chronic user of nonsteroidal anti-inflammatory drugs (nsaids) and/or acetaminophen for oa pain * if female and of childbearing potential, is nonlactating and nonpregnant exclusion criteria: * history of allergic reaction or clinically significant intolerance to acetaminophen, aspirin, or any nsaids, including meloxicam * requires continuous use of opioid or opioid combination products to control oa pain of the knee or hip * clinically significant unstable cardiac, respiratory, neurological, immunological, hematological, or renal disease * significant difficulties swallowing capsules or unable to tolerate oral medication * has received any investigational drug (except meloxicam solumatrix capsules), device, or therapy within 30 days before screening
axillary lymph node preservation surgery in reducing lymphedema in patients with breast cancer

Conditions: Breast Cancer

Summary: this pilot phase i and randomized phase ii trial studies the best way to perform axillary lymph node preservation surgery and to see how well it works in preventing lymphedema in patients with breast cancer. lymph node mapping may help in planning surgery to remove breast cancer and affected lymph nodes. it is not yet known whether reverse mapping guided axillary lymph node dissection is more effective than standard axillary lymph node dissection in preventing lymphedema.

primary objectives: i. to produce a map of the lymphatic drainage of the upper extremity as it relates to breast drainage, to determine the proportion of women undergoing axillary lymphadenectomy at risk for lymphedema. ii. to determine if blue lymphatics contain lymph node metastases. iii. to evaluate the incidence of lymphedema and associated other surgical related quality of life in those undergoing this procedure as compared to the current standard of care. outline: this is a phase i study followed by a randomized phase ii study. pilot portion: patients receive isosulfan blue dye subcutaneously (sc) and then undergo reverse mapping-guided axillary lymph node dissection. randomized portion: patients are randomized to 1 of 2 treatment arms. arm i: patients receive isosulfan blue dye subcutaneously (sc) and then undergo reverse mapping-guided axillary lymph node dissection. arm ii: patients undergo standard axillary lymph node dissection and then receive isosulfan blue dye sc. after completion of study treatment, patients are followed up periodically.

Eligibility criteria:
inclusion criteria: - patients diagnosed with breast cancer with a planned axillary lymph node dissection planned for breast cancer exclusion criteria: * prior lymphedema in either arm * prior history of axillary surgery (except for sentinel node biopsies) * prior history of chest/axillary radiation * need for bilateral axillary node dissection surgery * prior neurologic deficits (either motor or sensory) in ipsilateral arm * known allergy to vital blue dyes * no prior diagnosis of inflammatory breast cancer * cannot be pregnant or planning to continue breast-feeding immediately after surgery

Keywords: breast cancer axillary mapping lymphedema
comparative effectiveness and tolerance of subliminal subthreshold transscleral cyclophotocoagulation

Conditions: Glaucoma

Summary: glaucoma, progressive optical neuropathy, is the leading cause of irreversible blindness in the world. glaucoma treatment aims to lower intraocular pressure (iop) by using medication, laser and surgery. patients suffering from refractory and advanced glaucoma with impaired visual field who are not good candidates for surgery, cadenced subcleral transscleral cyclophotocoagulation (cpctsi) is commonly used to reduce iop. the cpctsi consists in delivering short bursts of energy (in cycle) to the ciliary body, thus reducing production of aqueous humor. the energy gusts develop sequentially to a photocoagulating state in the pigmented epithelium. they are spaced by rest periods that allow surrounding tissue to cool down and remain below photocoagulative threshold, thus avoiding damage to surrounding tissue. some studies have shown that the risk of complications increases with higher energies. complications associated with cpctsi include prolonged intraocular inflammation, pain, intraocular hemorrhage, hypotonia, phthysis, decreased vision and sympathetic ophthalmia. severity of these complications depends on collateral damage inflicted on surrounding tissues: ciliary muscles, unpigmented epithelium and stroma of ciliary body. currently, cpctsi with a cycle ratio of 25% and 31.3% are used in surgical routine in ophthalmology. cycle ratio is ratio between duration of gusts and total duration of cycle (gusts and rest periods). at st. joseph's hospital, both cycle ratios are used and the choice is operator dependent. however, using cpctsi with a 25% cycle ratio could have fewer complications while maintaining similar efficacy. to our knowledge, there are no studies comparing these two cycle reports, although they are commonly used in practice. our objective is to compare the cpctsi with a cycle ratio of 25% and 31.3%.


Eligibility criteria:
inclusion criteria: * patients with refractory and advanced glaucoma, defined as iop \> 21 mmhg according to maximum tolerated medical treatment, with or without pre-glaucoma surgical procedures and a visual field \> 6 md * patients treated in the ghpsj ophthalmology department by a cpctsi with cycle ratios of 25% or 31.3% between january and july 2017 * patients who are poor candidates for additional filtration surgery or implantation of glaucoma drainage devices. exclusion criteria: * patients who underwent intraocular surgery in the 2 months prior to cpctsi * patients who have undergone conventional transscleral laser diode cyclophotocoagulation * patients who object to use of their data for this research.
effects of omt on premature physiological parameters

Conditions: Premature Infant; Physiological Stress

Summary: osteopathic manipulative treatment has been showed to reduce los in premature infants. despite the clinical effectiveness, lack of data and information on the physiological underpinning effects during the treatment has been revealed. the aim of the study is to explore the immediate physiological effects of osteopathic treatment on premature infants


Eligibility criteria:
inclusion criteria: * preterm infants exclusion criteria: * congenital/genetic disease * cardiovascular/neurological disease
genes involved in lipid disorders

Conditions: Lipid Disorders

Summary: background: - genes are the instructions our body uses to function. researchers can look for changes, or variants, in the genes. the goal of this study is to find new gene changes that lead to lipid disorders. older research methods looked at one or a few genes at a time. genomic sequencing looks at most of the genes at once. genomic sequencing may find the cause researchers haven t been able to find from past methods. objectives: - to better understand genetic causes of lipid disorders through genomic sequencing. eligibility: - people age 2 and older with unusual lipid disorders, and their relatives. design: * participants will be screened with a physical exam and medical history. they will have blood taken. they may give a saliva sample. * based on the screening test, researchers will chose 3-5 family members to perform the genomic sequencing. the sequencing will be done on a sample of dna collected during the blood draw and saliva sample. * participants may be invited to take part in other protocols that may involve imaging of their heart or blood vessels. they do not have to participate. if they do, they will sign a separate consent for those tests. * if a participant s family member cannot travel to the nih, the nih documents and consent will be reviewed during a teleconference. a blood or sputum kit will be mailed to them.

the primary purpose of this discovery protocol is to identify new lipid genes from subjects with rare genetic lipids disorders. we will take advantage of the new technology of whole exome sequencing to find the cause of dyslipidemia that we haven t been able to find using past methods. we will work with geneticists to review the sequence data for unexpected gene changes (incidental findings) that do not explain the lipid disorder but gene changes that can cause medical disorders such as rare forms of cancer or heart disease. the opportunity to participate in the clinical center genomics opportunity (ccgo) program will enable us to take advantage of our expertise in other rare lipid disorders and translate this knowledge into new diagnostics and therapies, which is a key mission of the nih.

Eligibility criteria:
* inclusion criteria: index cases to be included are those with unusual dyslipidemia. relatives of affected individuals may also be included as appropriate. child index: greater than or equal to 2 years older adult index: greater than or equal to18 years older child relatives (siblings, cousins): greater than or equal to 2 years older adult relative: greater than or equal to18 years older (biological parent, aunt, uncle or grandparent) exclusion criteria: 1. inability or unwillingness to provide informed consent or assent 2. prisoners or other institutionalized persons will not be allowed to participate. 3. children \<2 years of age.

Keywords: hypertriglyceridemia atherosclerosis genectic variants hyperalphalipoproteinemia dyslipidemia natural history
blastocystis and cryptosporidium infection in colorectal cancer patients

Conditions: Blastocystis Infection; Cryptosporidium Infection; Colorectal Cancer

Summary: 1. detect the prevelance of blastocystis spp. and cryptosporidium spp. among patients with colorectal cancer attending south egypt cancer institute-assiut university. 2. detect the effect of blastocystis and cryptosporidium infection on various cytokines level in crc patients that may be involved in the tumor progression.


Eligibility criteria:
inclusion criteria: * the persons selected for the study are those who are: 1. colorectal cancer confirmed patients by imaging techniques (ct or mri) and histopathological biopsy by colonoscopy. 2. cooperative individuals attending south egypt cancer institute - assiut university of all ages and both sexes with confirmed diagnosis of crc who agreed to be engaged in the study and were able to provide adequate samples. crc patients will be divided into 4 groups: group 1: crc patients without blastocystis or cryptosporidium infection. group 2 : crc patients with blastocystis infection. group 3 : crc patients with cryptosporidium infection. group 4 : crc patients with both blastocystis and cryptosporidium infection. exclusion criteria: * patients having any type of tumors other than crc. patients taking anti-parasitic medications 2 weeks before sample collection.
slowing the degenerative process, long lasting effect of hyperbaric oxygen therapy in retinitis pigmentosa

Conditions: Retinitis Pigmentosa

Summary: our aim was to assess the role and usefulness of hyperbaric oxygen therapy in a long lasting period, assessing its efficacy on rescuing retinal photoreceptors and preserving visual function in retinitis pigmentosa.


Eligibility criteria:
inclusion criteria: * patients with clearly hereditary rp (we performed to all of them genetic analysis for rhodopsin, and peripherin genes, only 4 patient with adrp showed point mutation 3 on codon 135 and 1 on codon 347); best corrected visual acuity (bcva) ≥ 0.50 logmar; visual field ≥ 3 degree diameter circle; recordable erg. exclusion criteria: * exclusion criteria were: patients with sporadic rp; bcva ≤ 0.50 logmar; visual field ≤ 3 degree diameter circle; not recordable erg.
prospective and monocentric study of the incidence of venous thromboembolic disease (vte) in spinal cord injury (sci) patient between 3 and 12 months after sci

Conditions: Spinal Cord Injury

Summary: venous thromboembolic disease (vte) in sci patients is very common, its prevalence is 60 to 80% against 10-20% in the general population. the risk of vte is very important in the first weeks after spinal cord injury, and then declines with a prevalence of vte slightly higher than the general population after 12 weeks. however there is no prospective study of incidence of vte in sci patients after 3 months. the investigators wish to conduct such a study during the year following spinal cord injury with performing venous doppler ultrasound of the lower limbs 6, 9 and 12 months of the initial injuryassociated with a standardized clinical assessment, to know the incidence of vte and determine prognostic factors for vte.


Eligibility criteria:
inclusion criteria: * age greater than 18 years. * patients having paraplegia or tetraplegia from c2 levels and above s1 * paraplegia and tetraplegia of traumatic or non progressive sci from traumatic or medical origin (ischemic, post-surgical, myelitis, benign tumor) * informed consent signed. * stabilized respiratory situation with absence of chronic hypoxemia (hypoxemia being characterized by pao2 steady state \<7.33 kpa) * patient not amputated. * absence of heart failure with ejection fraction below 30% * lack of solid neoplasia or progressive lymphoid haemopathy for 5 years, or myeloproliferative disorders (including polycythemia and thrombocythemia). * no personal history of vte and / or thrombophilia before the injury. exclusion criteria: * unstabilized respiratory situation with presence of chronic hypoxemia (hypoxemia being characterized by pao2 steady state \<7.33 kpa) * amputated patient. * patients with heart failure with ejection fraction below 30% * solid neoplasia or progressive lymphoid haemopathy for 5 years, or myeloproliferative disorders (including polycythemia and thrombocythemia). * personal history of vte and / or thrombophilia before the injury. * can not to follow during the study period * pregnant women * patient refusal
effect of aerobic training on quality of life in elderly with idiopathic chronic fatigue

Conditions: Chronic Idiopathic Fatigue

Summary: the study was conducted to evaluate the effectiveness of aerobic training for decreasing fatigue severity and increasing quality of life in elderly with idiopathic chronic

idiopathic chronic fatigue (icf) or chronic idiopathic fatigue (cif), this type of tiredness is ongoing and unrelated to any underlying medical or mental health issues. different diagnostic criteria apply to people with idiopathic chronic fatigue and those with chronic fatigue syndrome (cfs). regular aerobic exercise has been demonstrated to improve cardiopulmonary fitness, increase physical activity levels, and decrease the degree of fatigue in elderly patients with severe idiopathic fatigue.

Eligibility criteria:
inclusion criteria: * ages ranged from 60 to 70 years and they will have bmi in between25.0-29.9 kg/m2, * complaining fatigue least six months ago without identifying any specific cause for their fatigue. * could walk safely without the aid of another person. exclusion criteria: * renal, vascular, hepatic, autoimmune, heart, chest and thyroid disorders. * lower limb arthritis or any orthopedic problem will hinder the training. * cognitive impairment or psychological problems, * fatigue caused as a known side effect of medication. * any febrile condition and/or infectious diseases

Keywords: aerobic training
cardiac compass with optivol® to negate future inpatient re-admissions through monitoring in hf patients (confirm-hf)

Conditions: Heart Failure

Summary: a research study to determine if heart failure can be medically managed using data collected from cardiac monitoring devices


Eligibility criteria:
inclusion criteria: * at least 18 years of age * admission for worsening of hf * discharged to home * have appropriate cardiac device with optivol® implanted for at least 34 days prior to enrollment * enrolled in carelink® system and able to transmit data * able to participate for at least 3 months exclusion criteria: * post heart transplant or actively listed * end-stage (stage d) hf, including treatment with chronic ionotropic drugs or left ventricular assist device support * stage iv or v chronic renal dysfunction (gfr \<25 mol/min per 1.73 m2) * severe chronic obstructive pulmonary disease (copd) requiring home oxygen * severe pulmonary hypertension not due to left-sided hf

Keywords: heart failure optivol® cardiac device medtronic carelink
vitamin d deficiency and atopic dermatitis

Conditions: Atopic Dermatitis; Vitamin D Deficiency

Summary: atopic dermatitis is a chronic skin disease characterized by a defective skin barrier, inflammation, and increased propensity for skin infections. vitamin d is a fat-soluble vitamin that is primarily acquired through local production in the skin after ultraviolet light exposure but can also be obtained through natural and supplemental dietary sources. this randomized controlled trial will examine the effects of vitamin d repletion on atopic dermatitis severity in patients with diagnosed deficiency. the investigators hypothesize that pediatric patients with moderate or severe atopic dermatitis and vitamin d deficiency will have improved cutaneous disease after treatment with high dose as compared to standard dose vitamin d.


Eligibility criteria:
inclusion criteria: * serum 25-hydroxyvitamin d level \<20 ng/ml (\<50 nmol/l) * diagnosed with atopic dermatitis by a chw pediatric dermatologist * age 1-18 years old * primary residence in milwaukee county * moderate and severe atopic dermatitis (severity scoring of atopic dermatitis \[scorad\] score greater than 15) * on clinic protocol treatment for their atopic dermatitis (desonide ointment twice daily for the face and groin, triamcinolone 0.1% ointment twice daily for other areas)